The Stanford Cancer Center is applying to the National Cancer Institute (NCI) for five years of funding of a Cancer Center Support Grant (CCSG) and for designation as a Comprehensive Cancer Center. Over the past three years, the Cancer Center has grown from 260 to 311 members representing four Schools within Stanford University (Medicine, Engineering, Humanities and Sciences and Law) and the Northern California Cancer Center with which Stanford has had a long-standing, scientifically productive relationship under a formal affiliation agreement. The CCSG proposal is built upon institutional strengths in technology development, particularly in the fields of imaging, biotechnology, informatics, and chemical engineering. The integration of these research areas into the fields of cancer biology, immunology, genetics and stem cell biology in the development of new approaches to cancer prevention, diagnosis and treatment is the distinguishing feature of this Cancer Center. Ten programs cover the areas of basic, translational/clinical, and population science research in cancer (Cancer Biology, Radiation Biology, Cancer Stem Cells, Cancer Imaging and Early Detection, Molecular Therapeutics, Lymphoma and Hodgkin Disease, Cancer Immunology and Immunotherapy, Hematopoietic Cell Transplantation and Immune Reconstitution, Cancer Epidemiology, and Cancer Prevention and Control). Eleven Shared Resources support the basic and translational/clinical investigation that is carried out in the Center. Based on current NCI base funding of $36 million and with $58 million in other NIH support and $16 million in other peer-reviewed cancer-relevant funding, the Center is requesting $5.3 million in direct costs to support its activities. With the advent of two new buildings for basic and translational research, new recruitment, and increased collaborative interactions, the Center is poised to make significant contributions to cancer research in the new funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA124435-08S2
Application #
8917470
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2007-06-04
Project End
2015-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
8
Fiscal Year
2014
Total Cost
$323,044
Indirect Cost
$123,044
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72
Chiou, Shin-Heng; Kim-Kiselak, Caroline; Risca, Viviana I et al. (2014) A conditional system to specifically link disruption of protein-coding function with reporter expression in mice. Cell Rep 7:2078-86
Zhu, Gefei Alex; Danial, Christina; Liu, Andy et al. (2014) Overall and progression-free survival in metastatic basosquamous cancer: a case series. J Am Acad Dermatol 70:1145-6
Caswell, Deborah R; Chuang, Chen-Hua; Yang, Dian et al. (2014) Obligate progression precedes lung adenocarcinoma dissemination. Cancer Discov 4:781-9
Bartroff, Jay; Lai, Tze Leung; Narasimhan, Balasubramanian (2014) A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. Stat Med 33:2718-35
Kohrt, Holbrook E; Thielens, Ariane; Marabelle, Aurelien et al. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678-86
DiCarlo, Joseph; Agarwal-Hashmi, Rajni; Shah, Ami et al. (2014) Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 20:361-9
Chang, Serena; Kohrt, Holbrook; Maecker, Holden T (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713-9
Ansari, Celina; Tikhomirov, Grigory A; Hong, Su Hyun et al. (2014) Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 10:566-75, 417
Lavori, Philip W; Dawson, Ree (2014) Introduction to dynamic treatment strategies and sequential multiple assignment randomization. Clin Trials 11:393-399

Showing the most recent 10 out of 24 publications